Lazertinib: on the Way to Its Throne

Lazertinib is an oral, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that forms an irreversible covalent bond to the Cys797 residue in the ATP-binding site of the EGFR kinase domain and exhibits a high selectivity for sensitizing and T790M EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jiyun, Hong, Min Hee, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424779/
https://www.ncbi.nlm.nih.gov/pubmed/36031779
http://dx.doi.org/10.3349/ymj.2022.63.9.799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424779/
https://www.ncbi.nlm.nih.gov/pubmed/36031779
http://dx.doi.org/10.3349/ymj.2022.63.9.799

Ejemplares similares